Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
Hs 578T
TNBC
Basal B
Cetuximab
EGFR
ErbB
7861.018
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.8485
Hs 578T
TNBC
Basal B
Erlotinib
EGFR
ErbB
7475.091
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
2.6839
HCC1806
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7450.095
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
1.7844
LY2
HR+
Luminal
ZM-447439
AURK
AURK
10816.15
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.3031
LY2
HR+
Luminal
TCS PIM-1 1
Pim kinase
PIM
12319.135
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.3806
MDA-MB-361
HER2amp
Luminal
SB-3CT
MMP2/9
MMP
12379.168
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.4672
MDA-MB-175-VII
HR+
Luminal
Cetuximab
EGFR
ErbB
7884.018
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.6074
SUM185PE
TNBC
Luminal
Selumetinib
MEK
MAPK
12269.155
uM
inf
inf
1.0402 1.0402 0.0000 -0.0494
-252.5060
0.7969
SUM185PE
TNBC
Luminal
Cetuximab
EGFR
ErbB
7921.042
uM
inf
inf
1.0399 1.0399 0.0000 -0.0494
-236.5755
0.6355
MDA-MB-415
HR+
Luminal
Methotrexate
DHFR
Metabolism
7512.084
uM
inf
inf
1.0500 1.0500 0.0000 -0.0491
-524.0720
0.7511
SUM185PE
TNBC
Luminal
Cisplatin
DNA cross-linker
DNA cross-linker
10146.049
uM
inf
inf
1.0500 1.0500 0.0000 -0.0490
-376.2593
0.8861
HCC1419
HER2amp
Luminal
Cetuximab
EGFR
ErbB
7820.042
uM
inf
inf
1.0221 1.0221 0.0000 -0.0483
-28.6122
0.5216
HCC1428
HR+
Luminal
PS-1145
IKK
NFKB
7444.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0480
-32.1065
0.7419
MDA-MB-231
TNBC
Basal B
Sirolimus
MTOR
MTOR
7504.069
uM
inf
inf
1.0328 1.0328 0.0000 -0.0478
-66.7663
1.8361
HCC1187
TNBC
Basal A
LY294002
PI3K
PI3K
7812.029
uM
inf
inf
1.0500 1.0500 0.0000 -0.0475
-56.7271
0.9642
HCC1428
HR+
Luminal
PS-1145
IKK
NFKB
7443.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0474
-21.6708
0.8818
HCC1419
HER2amp
Luminal
Purvalanol A
CDK1
CDK
7437.067
uM
inf
inf
1.0500 1.0500 0.0000 -0.0473
-48.7760
0.4038
MDA-MB-175-VII
HR+
Luminal
(Z)-4-Hydroxytamoxifen
ESR1
7884.016
uM
inf
inf
1.0238 1.0238 0.0000 -0.0464
-32.8843
0.4603
MDA-MB-415
HR+
Luminal
Purvalanol A
CDK1
CDK
7511.067
uM
inf
inf
1.0500 1.0500 0.0000 -0.0461
-21.9241
1.1247
LY2
HR+
Luminal
PS-1145
IKK
NFKB
10380.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0461
-60.9713
1.4916
Hs 578T
TNBC
Basal B
Erlotinib
EGFR
ErbB
7472.092
uM
inf
inf
1.0174 1.0174 0.0000 -0.0459
-20.4790
1.2676
LY2
HR+
Luminal
Erlotinib
EGFR
ErbB
7477.091
uM
inf
inf
1.0500 1.0500 0.0000 -0.0458
-19.0433
1.1485
HCC1419
HER2amp
Luminal
Cetuximab
EGFR
ErbB
10019.124
uM
inf
inf
0.9810 0.9810 0.0000 -0.0457
-3.7312
0.5356
LY2
HR+
Luminal
AG1024
IGF1R
RTK
10380.066
uM
inf
inf
1.0500 1.0500 0.0000 -0.0457
-3.8399
1.2245
MCF 10F
NM
-
FTase Inhibitor I
Ftase
MAPK
12254.154
uM
inf
inf
1.0500 1.0500 0.0000 -0.0451
-13.9008
1.6307